Articles By RheumNow
Is Methotrexate Necessary with Tofacitinib?
By RheumNow
Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.
Read Article
Excess Non-CV Mortality Persists in Gout
By RheumNow
Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.
Read Article
Lupus Disease Control with Rituximab
By RheumNow
Rituximab (Rituxan) may be an option for maintenance therapy in patients with difficult-to-treat systemic lupus erythematosus (SLE), European researchers reported.
Read Article
Lung Disease in RA: Which Factors are Linked With Mortality?
By RheumNow
Among patients with rheumatoid arthritis (RA) who had interstitial lung disease (ILD), the pattern of ILD did influence mortality, but other pulmonary factors also contributed, a meta-analysis suggested.
Read Article
Risk Score Predicts Thrombosis Recurrence in APS
By RheumNow
A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.
Read Article
Biomarkers Predict Thrombosis in Lupus
By RheumNow
A composite risk score that included three biomarkers predicted thrombotic events among patients with systemic lupus erythematosus (SLE), a cross-sectional study found.
Read Article
Denosumab Protects Against RA Erosions
By RheumNow
Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.
Read Article
Shorter Treatment Succeeds in Septic Arthritis
By RheumNow
Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.
Read Article
Targeting GM-CSF Works in Rheumatoid Arthritis
By RheumNow
Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.
Read Article
Smoking Not Protective Against Knee OA
By RheumNow
Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark.
Read Article